The Evidence for Intravenous Theophylline Levels between 10-20mg/L in Children Suffering an Acute Exacerbation of Asthma: A Systematic Review by Cooney, Lewis et al.
RESEARCH ARTICLE
The Evidence for Intravenous Theophylline
Levels between 10-20mg/L in Children
Suffering an Acute Exacerbation of Asthma:
A Systematic Review
Lewis Cooney1, Daniel Hawcutt1,2☯*, Ian Sinha2☯
1 Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool,
Liverpool, Merseyside, United Kingdom, 2 National Institute for Health Research Alder Hey Clinical
Research Facility, Alder Hey Children’s Hospital, Liverpool, Merseyside, United Kingdom
☯ These authors contributed equally to this work.
* dhawcutt@liverpool.ac.uk
Abstract
Background
Intravenous theophyllines are a second line treatment for children suffering an acute
exacerbation of asthma. Various guidelines and formularies recommend aiming for serum
theophylline levels between 10-20mg/l. This review aims to assess the evidence underpin-
ning this recommendation.
Methods
A systematic review comparing outcomes of children who achieved serum theophylline con-
centrations between 10-20mg/l with those who did not. Primary outcomes were time until
resolution of symptoms, mortality and need for mechanical ventilation. Secondary out-
comes were date until discharge criteria are met, actual discharge, adverse effects and
FEV1.
Data sources
MEDLINE, CINAHL, CENTRAL andWeb of Science. Search performed in October 2015.
Eligibility criteria
Interventional or observational studies utilizing intravenous theophyllines for an acute
exacerbation of asthma in children where serum theophylline levels and clinical outcomes
were measured.
Findings
10 RCTs and 2 observational studies were included. Children with serum levels between
10-20mg/l did not have a reduction in duration of symptoms, length of hospital stay or need
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for mechanical ventilation or better spirometric results compared with levels <10mg/l. Levels
above 20mg/l are not associated with higher rates of adverse effects. This study is limited
due to heterogeneity in the way theophylline levels were reported and poor surveillance of
adverse effects across studies.
Conclusion
Dosing strategies aiming for levels between 10-20mg/l are not associated with better out-
comes. Clinicians should rely on clinical outcomes and not serum levels when using intrave-
nous theophyllines in children suffering an acute exacerbation of asthma.
Introduction
Asthma is a disorder of widespread lower airway inflammation and obstruction that is revers-
ible either spontaneously or with treatment. Asthma affects around 235 million people world-
wide and is a common cause of hospital admission in children [1]. In an acute exacerbation,
inhaled medication may fail to control symptoms, resulting in potentially life threatening air-
ways obstruction [2]. Intravenous theophyllines can be used as second-line therapy for children
who do not respond to inhaled bronchodilators and systemic corticosteroids [3]. Aminophyl-
line is a mixture of theophylline, which is the active compound that causes bronchodilation by
poorly understood mechanisms [4], and ethyldiamine, an excipient which confers greater solu-
bility in water. Intravenous preparations of theophylline have also been developed with differ-
ent excipients to minimize potential allergic reactions.
It is advised that serum levels of theophylline should be measured, as it is purported to have
a narrow therapeutic range, and its pharmacokinetic properties vary between patients [5,6].
The most recent guidelines and formularies recommend a therapeutic range between 10-
20mg/l and a loading dose of 5mg/kg for children who do not take oral theophylline regularly
[3,7]. This therapeutic range appears to have been originally based on studies demonstrating
improvements in spirometry in adults with theophylline levels above 10mg/l [8–10]. As phar-
macological properties of drugs change with age, this may not necessarily be appropriate in
children. Furthermore, aminophylline is used in children with severe asthma attacks to prevent
deterioration and resolve clinical symptoms, rather than improve physiological measures of
lung function. We aimed to appraise the evidence for the current therapeutic range of ami-
nophylline in children with acute asthma (10–20 mg/l).
Materials and Methods
Study design
We conducted a systematic review (S1 File) of studies investigating the use of intravenous the-
ophyllines in acute asthma in children that report both relevant clinical outcomes and theoph-
ylline levels.
Methods of the review
We included parallel and crossover randomized controlled trials (RCTs) comparing two or
more therapeutic ranges for intravenous theophyllines in children and adolescents (aged 19 or
younger) with acute asthma. We also included RCTs comparing intravenous theophyllines
with placebo, if a measure of serum theophylline levels was reported for the two treatment
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groups, and we included retrospective or prospective observational studies if they reported
results for both clinical outcomes and therapeutic levels measured in the included children.
We excluded studies including adults (20 years and older) and children unless the paediatric
data were reported separately, and studies utilizing theophyllines for an indication other than
asthma (e.g. neonatal apnoea and tuberculosis).
Outcomes
The prespecified primary outcomes were time until resolution of symptoms, need for mechani-
cal ventilation, and mortality [11]. Secondary outcomes were days until discharge criteria are
met, actual discharge from hospital, adverse effects as defined and reported by authors, and
forced expiratory volume in one second (FEV1). Studies must report at least one outcome to
meet our inclusion criteria.
Identification of studies. The following search strategy was used to search MEDLINE,
CINAHL, The Cochrane Central Register of Controlled Trials, and Web of Science in Septem-
ber 2015, with no date or language restrictions: ((aminophylline OR xanthine OR phyllocontin
OR theophylline OR pde4 inhibitor OR phosphodiesterase 4 inhibitor OR caffeine) and (intra-
venous OR IV OR parenteral) AND (acute asthma OR asthmaticus OR severe asthma OR "hos-
pitaled" OR asthma attack") AND (child OR adolescen OR infan OR pediatric))
One reviewer (LC) screened all abstracts. A second reviewer (IS or DH) checked the eligibil-
ity of abstracts after initial screening, and full studies included in the review. Reference lists
were screened for other eligible studies.
Data extraction and analysis
From each study we identified the theophylline levels achieved in the research participants
(and when these were measured) and, if stated, the desired target range. We extracted data
around the outcomes listed above, at whichever timepoints they were reported. We also
recorded the age range of participants. From RCTs, exclusion criteria, control medication, con-
comitant medication and statistical significance of results were also noted.
We anticipated methodological and reporting heterogeneity between studies so we planned
a priori that the results of the review would be presented descriptively.
The primary analysis was of RCTs comparing therapeutic ranges of theophylline, in which
we aimed to compare clinical outcomes between groups. The secondary analyses were of RCTs
comparing theophylline with placebo, and observational studies. In these studies, we tabulated
results for our prespecified clinical outcomes (for RCTs, we recorded the magnitude of differ-
ence in outcome between theophylline and placebo), alongside either the mean or median
serum theophylline level measured in the group, or the proportion of participants whose levels
were within a predefined target therapeutic range. We assessed whether those RCTs in which
mean or median theophylline levels were>10 mg/l reported more benefit than those in which
the measured level was<10 mg/l, and whether those studies reporting levels>20 mg/l
appeared to demonstrate a higher incidence of adverse effects.
Data was extracted by primary investigator LC and reviewed by DH. Any disagreements
regarding the extraction process were resolved by consensus, or arbitration by reviewer IS.
Assessment of quality of included studies
The Cochrane Risk of Bias Tool [12] was applied to each RCT, to help determine the validity of
results. The critical appraisal skills programme (CASP) tool was used to appraise the quality of
observational studies. We also evaluated whether authors described how they monitored indi-
vidual children for adverse effects, and how thorough this surveillance was [13].
Theophylline Levels in Children with Acute Asthma
PLOSONE | DOI:10.1371/journal.pone.0153877 April 20, 2016 3 / 14
Results
A total of 488 studies were found using the search criteria, with 22 full text articles screened for
eligibility. We excluded 10 full text articles (S2 File) with the remaining 12 articles included in
the review (Fig 1).
We found no RCTs comparing different therapeutic ranges of theophylline. We included
ten RCTs comparing theophylline with placebo, and two retrospective observational studies.
Quality of included studies
Of the ten randomized controlled trials, two gave no data on adverse effects [14,15], 2 reported
side effects unsystematically [16,17] and six reported adverse effects thoroughly using prospec-
tive methods clearly outlined in the methodology [18–23].
The results of the Cochrane risk of bias assessments conducted on the ten RCTs comparing
intravenous theophyllines with placebo are shown in Table 1. Three studies were classed at
Fig 1. Search results.
doi:10.1371/journal.pone.0153877.g001
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high risk of attrition bias, one at high risk of reporting bias with respect to symptom scores,
and three at high risk of reporting bias of adverse outcomes. In general, the other domains of
bias were classified as low or unclear risk in most studies.
The CASP assessments conducted on the two observational studies are presented in Table 2
Clinical outcomes
The theophylline levels reached, primary outcomes and secondary outcomes are shown in
Tables 3 and 4.
Clinical outcomes in context of theophylline levels
Of 10 RCTs six gave an optimal therapeutic range for theophylline: three studies aimed for
serum concentrations between 10 and 20mg/l [14,19,21] one study of 15mg/l [23], one between
Table 1. Assessment of risk of bias in included studies using Cochrane tool.
D’Áliva
2008
Ream
2001
Nuhoglu
1998
Yung
1998
Bien
1995
Needleman
1995
Strauss
1994
Carter
1993
DiGiulio
1993
Pierson
1971
Random sequence
generation (selection bias)
? # ? # # ? ? ? ? ?
Allocation concealment
(selection bias)
# " ? # ? # ? ? ? #
Blinding of participants
(performance bias)
# " # # # " ? " # #
Blinding of outcome
assessment (performance
bias)
# # # # ? # # ? ? #
Incomplete outcomes
assessed (attrition bias)
? " # # # " " # # ?
Selective outcome
reporting (symptom
scores/spirometry)
# # # # # # # # # "
Selective outcome
reporting (adverse
reactions
# # " # # " # # " "
# low risk of bias, " high risk of bias, ? unclear risk of bias
doi:10.1371/journal.pone.0153877.t001
Table 2. Assessment of quality in observational studies.
Retrospective studies Dalabih 2014 Fox 1982
Clearly focused issue # #
Acceptable recruitment # #
Adequate exposure measurement # #
Adequate outcome measurement # #
confounding factors identiﬁed " "
Complete follow up? " "
Result precision ? ?
Believable results # #
Applicable to local population # #
Consistent with other evidence ? #
# low risk of bias, " high risk of bias, ? unclear risk of bias
doi:10.1371/journal.pone.0153877.t002
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12-17mg/l [18] and one between 12-20mg/l [16]. Of the observational studies one defined tar-
get therapeutic levels as 10mg/l or greater [24] and one as 10-20mg/l [25].
There was non uniformity in the timing of theophylline level measurement. Of the random-
ized controlled trials, three measured serum levels 30 minutes after completion of the loading
dose [14,22,23], three after one hour of completion of the loading dose [18–20], and one six
hours after completion of loading dose [16]. One RCT and neither observational study did not
stipulate when theophylline were taken [5,17,21]. Serum levels were measured in all partici-
pants receiving theophylline, except in one study, where only 17% of those in the intervention
group had serum theophylline levels measured [15].
There was heterogeneity between studies in the way in which theophylline levels were
reported. Five studies presented the mean theophylline level achieved [16,16,81,21,22], three
gave the proportion of research participants who were below/above the target range [20–24,
25] and four gave the range of theophylline levels achieved [14,17,19,23].
Table 4. Results of Observational studies.
Primary
outcomes
Secondary
outcomes
First
author,
Location,
age range
of
participants
Study design Timing of
theophylline
level
measurement
Theophylline
levels
achieved
Time until
resolution of
symptoms
Need for
mechanical
ventilation
Date until
discharge
criteria are
met
Actual
discharge
Adverse
effects
Spirometry
Fox 1982,
USA,1–16
years
Retrospective
analysis of
patients'
theophylline
levels on
subsequent
therapeutic
decisions
Not measured <10mg/l in 20
patients 10-
20mg/l in 14
patients, no
patients had
levels >20mg/l
Not measured Not
measured
Not
measured
3.25 days 3 patients
with
theophylline
levels
20.5mg/l,
21.1mg/l and
25.6mg/l non
showed
signs of
theophylline
toxicity
Not
measured
Dalabih
2014, USA,
3–18 years
Retrospective
analysis of
critical care
patients
admitted with
an acute
exacerbation of
asthma were
compared with
similar patients
who did not
Not measured 31 had
theophylline
levles10mg/l,
18 had
theophylline
levels10mg/l
Time to reach
RDS*7
longer in those
who received
aminophylline
compared to
those who did
not
(HR = 0.359
95% CI [0.223,
0.578]
p<0.001.
Longer in those
with levels 10-
20mg/l
HR = 0.403 CI
[0.204, 0.739]
p = 0.008
Not
measured
Not
measured
Aminophylline
associated with
longer stay in
critical care
HR = 0.396 CI
[0.245, 0.64]
p<0.001.
Among those
who receive
aminophylline
length of stay
was longer
HR = 0.457 CI
[0.234, 0.895]
p = 0.023
Not
measured
Not
measured
RDS—Respritory distress score, HR—hazard ratio, CI—conﬁdence interval
doi:10.1371/journal.pone.0153877.t004
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Primary Outcomes
1) Time until resolution of symptoms. Of the ten RCTs, two reported time until resolu-
tion of symptoms as an outcome [18–26], four measured change in asthma score over a given
time [14,19,21,23] and four did not measure symptoms. Various symptom scores were used
(Table 4).
There appeared to be no difference in the magnitude of results when comparing levels of
serum theophylline measured in participants. In one RCT demonstrated that symptom
improvement was quicker in those receiving theophylline compared with placebo (18.6±2.7h
vs 31.1±4.5h [p<0.05], mean serum theophylline levels 11.2mg/l) [18] but this was not repli-
cated in another study in which similar serum theophylline levels were reported (30.4±16.8h vs
27.0±10.3h [p = 0.51], mean serum theophylline level 13.1mg/l) [16] No studies demonstrated
a statistically significant improvement of symptoms after 2, 6, 12, 24, 48 and 36 hours at any
serum theophylline level [14, 19, 21–23].
One retrospective study [24] measured time until symptom improvement and found that
this appeared to be longer after treatment with aminophylline (hazard ratio 0.359, p< 0.001).
The authors also note that this was significantly more prolonged in those with levels>10mg/l
compared to those who are subtherapeutic (hazard ratio 0.403 p = 0.0085).
2) Need for mechanical ventilation. No studies compared the effect of IV aminophylline
against placebo, in non-intubated children, on the subsequent need for mechanical ventilation.
3) Mortality. There were no reported deaths in any study.
Secondary outcomes
1) Date until discharge criteria are met. One study reported time until children were
ready for discharge home and found no significant difference between theophylline and pla-
cebo (27.0±10.3 hours vs 30.4±16.8 hours [p>0.05]. Mean theophylline level 13.1mg/l) [16].
Another study measured time to meet discharge criteria from the intensive care unit, but not
time until discharge home. The study reported a statistically significant difference in favour of
aminophylline (29.8±4.9h vs 36.4±5.5h [p<0.05]. Mean daily theophylline level = 14.5 ± 0.7
mg/L, target theophylline levels 12-17mg/l) [18].
2) Actual discharge. Four studies recorded length of time in hospital as an outcome. One
study, in which mean theophylline levels were 7.2mg/l [15] and one study with mean levels of
12.3mg/l [20] demonstrated no statistically significant difference in length of hospital stay
when compared to placebo. One trial demonstrated a significant improvement in length of stay
in critical care in the aminophylline group compared with placebo (3.9±0.3 days versus 8.8±1.5
days in placebo [p<0.05] mean serum theophylline level 11.2mg/l), but not in discharge home
(8.3±1.5 days versus 13.0±1.0 days [p>0.05] mean serum theophylline level 11.2mg/l). This
study demonstrated a significantly shorter length of stay in critical care in the very small subset
of intubated patients receiving aminophylline compared to those receiving placebo [18].
One retrospective study found that length of stay in critical care was longer for subjects
receiving aminophylline (hazard ratio 0.396, [p = 0.001], 63% of participants>10mg/l) but
does not follow up patients until discharge home. Of those receiving aminophylline, those
found to have levels>10mg/l were found to have a longer stay in the intensive care unit com-
pared to those who with levels<10 mg/l [24]. Another retrospective study reported the mean
length of stay of hospital for patients receiving aminophylline was 3.25 days, but no compari-
son is made between those achieving different serum theophylline levels [25].
3) Adverse effects. Eight RCTs reported adverse effects. Three studies demonstrate statis-
tically significantly higher rates of adverse effects in those receiving intravenous theophyllines
compared to placebo [20–22] whilst an other study demonstrates no significant difference [19].
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In the few research participants with supratherapeutic theophylline levels (>20 mg/l) there did
not appear to be an increased risk of side effects. One retrospective study reported no adverse
effects in any of its supratherapeutic patients [25]. and one study links adverse effects to an
individual participant who experienced nausea and abdominal pain with levels of 23mg/l [22].
4) Spirometry. Three studies reported FEV1 as an outcome. Two studies demonstrated
significant improvements in FEV1 in the theophylline group compared to placebo (22.5% vs
13.1% [p = 0.029], serum level of participants 10-20mg/l) [20] (89% vs 62% [p<0.001], serum
level of participants 5-15mg/l) [17] whilst another study with theophylline levels between 10-
20mg/l demonstrated no statistically significant difference in FEV1,[23] In other studies, a
large proportion of participants were unable or unwilling to perform spirometry
Discussion
There is no evidence to suggest that 10–20 mg/l of theophylline is the optimal target serum
range in children with severe acute asthma. Across studies comparing aminophylline to pla-
cebo there appears to be no difference in outcome between concentrations of 10–20 mg/l and
<10mg/l. There is weak evidence to suggest that levels>20 mg/l are associated with in increase
in abdominal pain, nausea and vomiting. There is insufficient evidence to suggest that higher
serum levels could result in an improvement of symptoms.
This review demonstrates that there is an unclear relationship between serum levels and
either clinical efficacy or development of adverse effects. For evidence based therapeutic range
to be determined, there is a need for RCTs comparing ranges and measuring important clinical
outcomes, to determine the optimal dose in children. Until there is clear evidence that the ben-
eficial serum level of theophylline lies within a certain range, rigorous evaluation of clinical
progress and adverse drug effects should be used to guide therapy rather than laboratory
investigations.
Data suggests that a 5mg/kg loading dose would leave one third of children would be below
10mg/l, and none above 20mg/l [27] Routine measurement of serum theophylline levels in
children suffering acute asthma who have received standard loading doses of aminophylline to
achieve serum concentrations in the 10-20mg/L range is therefore unlikely to result in any clin-
ical benefit or reduction in adverse effects. However measurement of serum theophylline in
childhood acute severe asthma may still retain utility in the assessment of patients in whom
there is concern about overdose.
As we were unable to identify any RCTs directly comparing target ranges of theophylline,
our analyses incorporate indirect observational comparison across studies.
This review was hindered by inconsistencies between studies in measurement and reporting
of serum theophylline levels, and poor measurement of outcomes that are consistent with up to
date research investigating clinically relevant outcomes in childhood asthma [11]. Further-
more, our included studies span a 43 year time period and changes clinical practice, adminis-
tration of IV aminophylline and the selection of outcomes present further challenges when
comparing results. All of these issues contribute to data heterogeneity. Meta analysis was con-
sidered but is unlikely to provide further insight into the optimum therapeutic range of
aminophylline.
Research in children presents specific challenges such as potential difficulty in reporting
subjective side effects and reluctance to take blood samples, so monitoring of adverse effects
may be difficult. We agree with the a need for consistent reporting of adverse effects in clinical
trials [13]. A core outcome set is needed to measure and report outcomes in all trials. This
should be developed using rigorous consensus methodology [28] and would help interpretation
of studies, enable synthesis across trials, and reduce reporting bias [29].
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Conclusion
There is no evidence that theophylline levels above 10mg/l compared with levels below 10mg/l
are associated with improvement in children with severe acute asthma, nor that levels below
20mg/l are associated with less adverse effects than higher levels. Even if theophylline levels are
measured, we recommend that clinicians should be guided by clinical improvement, and be
vigilant to adverse effects, rather than simply titrate the dose according to serum levels. High
quality RCTs are required to compare therapeutic ranges of intravenous theophylline in chil-
dren, and these should measure and report a standardized core set of validated outcome mea-
sures reflecting both benefits and harms.
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